Abstract:Abstract 1570 Poster Board I-594 Acute myeloid leukemia with normal cytogenetics (CN-AML) represents approximately 40-50% of de novo AML cases and constitutes the single largest cytogenetic group of AML. CN-AML is composed of a heterogeneous group of AML considered to be more or less in the intermediate prognostic category. Stratified prognostic determinants are required to predict which patients in this heterogeneous category have an increased risk of relapse, resistance to therapy or long term disease outcomes. The CCAAT enhancer binding protein alpha (C/EBPA) is a key transcription factor involved in regulation of granulocytic differentiation and myelopoiesis. In the past few years, various studies have suggested that C/EBPA is negatively regulated in certain AML patients. Impairments in C/EBPA signaling such as gene mutation, transcriptional dysregulation, as well as epigenetic modification via promoter hypermethylation have been identified in CN-AML and these alterations may play an important role in pathogenesis and may predict prognosis in these patients. In the current study, we investigated C/EBPA gene mutations and promoter hypermethylation in a series of 53 patients with CN-AML. In addition, we also analyzed two other frequent mutations (FLT3/ITD and NPM1) in these patients and correlated them with C/EBPA gene alterations. Genomic DNA was isolated from diagnostic bone marrow and peripheral blood samples. The C/EBPA gene mutations were detected by PCR amplification followed by direct DNA sequencing while the promoter hypermethylation was characterized by methylation-specific PCR analysis. The FLT3/ITD mutation and NPM1 mutation were detected by using multiplex PCR followed by capillary electrophoresis. The study included 28 female patients and 25 male patients, all adults, with a median age of 49 years. 13/53 (24.5%) patients were FLT3/ITD+/NPM1-, 11/53 (20.8%) patients were FLT3/ITD+/NPM1+, 9/53 (17.0%) patients were FLT3/ITD-/NPM1+, and 20/53 (37.7%) patients were FLT3/ITD-/NPM1-. Four out of the 53 cases (7.5%) displayed C/EBPA mutations, whereas 49 (92.5%) cases had only C/EBPA wild-type alleles. Of the 4 positive cases, three patients had N-terminal mutations only, while one patient had mutations in both the N- and C-terminal region. Two of the 4 positive cases also harbored both FLT3/ITD and NPM1 mutation simultaneously, while the other two patients had neither FLT3/ITD nor NPM1 mutations. In addition, 7 (13.2%) of the 53 cases displayed C/EBPA promoter hypermethylation. Interestingly they were all in CN-AML cases without FLT3/ITD or NPM1 mutations. None of the 7 patients with C/EBPA promoter hypermethylation showed C/EBPA mutation. In conclusion, C/EBPA mutation and promoter hypermethylation can be detected at a relatively low frequency in de novo CN-AML patients, suggesting they may contribute to leukemogenesis. C/EBPA mutation appears to be frequently seen “high-risk” AML (FLT3/ITD+/NPM1+; FLT3/ITD+/NPM1- or FLT3/ITD-/NPM1-), while C/EBPA hypermethylation appears to be more common in AML with FLT3/ITD- /NPM1- and is not associated with C/EBPA mutation. The clear prognostic relationship of C/EBPA alteration and FLT3/ITD, NPM1 mutation needs to be further validated. Disclosures No relevant conflicts of interest to declare.

EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma

Identification of C/EBPβ target genes in ALK+ anaplastic large cell lymphoma (ALCL) by gene expression profiling and chromatin immunoprecipitation

C/Ebp Alpha Regulates Osteoclast Lineage Commitment

Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma

CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL

C/Ebpa Gene Mutation and C/Ebpa Promoter Hypermethylation in Acute Myeloid Leukemia with Normal Cytogenetics.

ALK-positive large B-cell lymphoma: a clinicopathological and molecular characteristics analysis of seven cases

Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma

Expression of Alk Protein, Mrna and Fusion Transcripts in Anaplastic Large Cell Lymphoma

Aberrant Expression of and Cell Death Induction by Engagement of the MHC-II Chaperone CD74 in Anaplastic Large Cell Lymphoma (ALCL)

ALK-negative Anaplastic Large Cell Lymphoma with Extensive Peripheral Blood and Bone Marrow Involvements Manifested As "leukemic Phase".

Microrna Expression Profiling Identifies Molecular Signatures Associated with Anaplastic Large Cell Lymphoma

CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma

Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma

NPM-ALK Inhibits the P53 Tumor Suppressor Pathway in an MDM2 and JNK-dependent Manner.

A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening

ALK-Negative Anaplastic Large Cell Lymphoma: Current Concepts and Molecular Pathogenesis of a Heterogeneous Group of Large T-Cell Lymphomas

PD-L1 Expression is Associated with ALK Positivity and STAT3 Activation, but Not Outcome in Patients with Systemic Anaplastic Large Cell Lymphoma

ALK-positive Large B-Cell Lymphoma With Multiple Epithelial Antigen Expression and PABPC1::ALK Fusion : A Novel Molecular Alteration

The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL)

Super-enhancer-based identification of a BATF3/IL-2R−module reveals vulnerabilities in anaplastic large cell lymphoma